Transarterial Chemoembolization with Anthracyclines-Loaded Polyethylene Glycol Drug Eluting Microspheres for the Treatment of Hepatocellular Carcinoma: A Pooled Multicentric Analysis of Survival in 580 Patients

[1]  J. Bruix,et al.  POLYETHYLENE-GLYCOL DRUG-ELUTING EMBOLIC MICROSPHERES LOADED WITH DOXORUBICIN FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: FEASIBILITY, SAFETY AND PHARMACOKINETIC STUDY. , 2022, Journal of vascular and interventional radiology : JVIR.

[2]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.

[3]  Andrés García-Gámez,et al.  Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience , 2021, Hepatic oncology.

[4]  J. Bruix.  End-points in clinical trials for liver cancer and their value in evidence based clinical decision making: an unresolved Gordian knot. , 2021, Journal of hepatology.

[5]  R. Lencioni,et al.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma , 2021, Nature Reviews Gastroenterology & Hepatology.

[6]  M. Ronot,et al.  Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry , 2020, Cancers.

[7]  J. Bruix,et al.  Local and Regional Therapies for Hepatocellular Carcinoma , 2020, Hepatology.

[8]  M. Kudo,et al.  Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial , 2019, Gut.

[9]  J. Bruix,et al.  Insights into the success and failure of systemic therapy for hepatocellular carcinoma , 2019, Nature Reviews Gastroenterology & Hepatology.

[10]  C. Catalano,et al.  Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results , 2019, CardioVascular and Interventional Radiology.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[13]  T. Bilhim,et al.  Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients. , 2018, Journal of vascular and interventional radiology : JVIR.

[14]  H. Pommergaard,et al.  Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry , 2018, Transplant international : official journal of the European Society for Organ Transplantation.

[15]  T. Bilhim,et al.  Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment. , 2018, Acta medica portuguesa.

[16]  M. Kudo,et al.  Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. , 2018, The lancet. Gastroenterology & hepatology.

[17]  C. Aliberti,et al.  Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. , 2017, Journal of vascular and interventional radiology : JVIR.

[18]  G. Fiorentini,et al.  Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma. , 2017, AJR. American journal of roentgenology.

[19]  R. Duran,et al.  Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion , 2017, European Radiology.

[20]  V. Catalano,et al.  B24Hepatic arterial infusion of Polythylene Glycol drug-eluting beads for Primary liver cancer therapy , 2016 .

[21]  T. de Baère,et al.  An In Vitro Evaluation of Four Types of Drug-Eluting Microspheres Loaded with Doxorubicin. , 2016, Journal of vascular and interventional radiology : JVIR.

[22]  Riccardo Lencioni,et al.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. , 2016, Journal of hepatology.

[23]  M. Kudo,et al.  Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial , 2014, Hepatology.

[24]  C. Bartolozzi,et al.  Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma , 2014, British Journal of Cancer.

[25]  Osamu Matsui,et al.  Comparison of Local Control in Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma ≤6 cm With or Without Intraprocedural Monitoring of the Embolized Area Using Cone-Beam Computed Tomography , 2014, CardioVascular and Interventional Radiology.

[26]  Y. Inaba,et al.  Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? , 2012, Japanese Journal of Radiology.

[27]  T. de Baère,et al.  Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. , 2012, Journal of hepatology.

[28]  Y. Shin,et al.  Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. , 2012, Radiology.

[29]  K. Kichikawa,et al.  Long-Term Outcome of Transcatheter Subsegmental and Segmental Arterial Chemoemobolization Using Lipiodol for Hepatocellular Carcinoma , 2012, CardioVascular and Interventional Radiology.

[30]  J. Bruix,et al.  Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques , 2011, Hepatology.

[31]  T. Vogl,et al.  Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations , 2011, CardioVascular and Interventional Radiology.

[32]  L. Mariani,et al.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. , 2009, The Lancet. Oncology.

[33]  J. Bruix,et al.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.

[34]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[35]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .